Dariohealth reports second quarter 2022 financial and operating results

Q2 revenue of 6.2 million, a 17.5% increase from the $5.3 million of the second quarter of 2021. six-month year-to-date revenue totaled $14.2 million, a  60.8% increase over the first six months of 2021 $55 million in total commercial contract value reflecting continued strong momentum across business-to-business-to-consumer (b2b2c) channels selected by a national health plan as strategic behavioral health partner, providing reach to nearly ten million additional members sanofi and other strategic partnerships gaining traction and expected to accelerate recurring revenue streams from employers and health plans improved financial profile as company completes shift to b2b2c focus and reports $68 million of cash and equivalents on the balance sheet as of june 30 company to host conference call and webcast 8:30 am et today new york , aug. 15, 2022 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital therapeutics (dtx) market, today reported financial results for the second quarter 2022 and provided a corporate and commercial update.
DRIO Ratings Summary
DRIO Quant Ranking